Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
posted
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Galapagos NV (Euronext: GLPG) announces today that it has been awarded a €3.7 million grant from the Flemish agency for Innovation by Science and Technology (IWT). read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that it has raised € 2.8 million as the result of the exercise of warrants by a number of the Company’s employees. The 289,000 shares created as a result of this warrant exercise are now listed on Euronext Brussels. Following this transaction, ThromboGenics now has 29,445,234 shares outstanding. read more
Galapagos NV (Euronext: GLPG) announces that it has completed its capital increase by issuing today 2,389,347 new ordinary shares. These shares will be delivered to Belgian and international institutional and other eligible investors who participated in the €28.7 million private placement closed earlier this week. The newly issued shares will be admitted to listing on NYSE Euronext Brussels/Amsterdam on 25 October 2010. read more
